Quercetin and 6-Br_uercetin antioxidant properties and off target screening results advance glycosylated 6BrQ as a development candidate for Alzheimers disease

This study demonstrates that the quercetin analog 6-bromoquercetin (6BrQ) possesses antioxidant properties equivalent to quercetin, exhibits a favorable off-target profile at low concentrations, and shows promising multi-target mechanisms relevant to Alzheimer's disease, thereby supporting its development as a glycosylated prodrug candidate.

The Gist

The Big Picture: A "Super-Ingredient" Upgrade

Imagine Quercetin is like a popular, old-school herbal tea. It's been around for a long time, and we know it's good for you. Studies suggest that people who drink a lot of flavonol-rich foods (like onions, apples, and berries) are less likely to get Alzheimer's disease.

However, there's a catch: Quercetin is a bit like a shy guest at a party. It doesn't stick around in your body very long, and it doesn't always get to the specific room (the brain) where it's needed most.

Enter 6-Br-Quercetin (6BrQ). Think of this as the "Super-Tea" or the upgraded version of the original ingredient. Scientists took the original Quercetin and added a tiny chemical "turbo-charger" (a bromine atom) to make it better at its job.

This paper is the report card for both the original tea and the Super-Tea. The researchers wanted to answer two main questions:

1. Does the Super-Tea still have the same "health shield" (antioxidant) powers as the original?
2. Does the Super-Tea accidentally mess with other systems in the body (off-target effects)?

---

1. The "Rust Shield" Test (Antioxidant Properties)

The Concept:
Your body is like a car. Over time, rust (oxidation) builds up on the metal, causing damage. Antioxidants are like a high-tech rust-proofing spray that stops this damage. In the brain, this "rust" is linked to Alzheimer's.

The Experiment:
The scientists put both Quercetin and 6BrQ into a lab test to see how well they stop the "rust."

The Result:
It turns out, the Super-Tea is just as good at stopping rust as the original tea. They are equal partners in this defense. The modification didn't break the "rust-proofing" ability; it kept it 100% intact.

---

2. The "Bouncer" Test (Off-Target Screening)

The Concept:
Imagine your body is a massive nightclub with 104 different VIP rooms (receptors, enzymes, and transporters). Each room has a specific bouncer.

• Good drugs knock on the right door (the target) and get in.
• Bad drugs (or drugs with side effects) knock on the wrong doors, causing chaos in rooms they shouldn't be in.

The researchers wanted to see if Quercetin and 6BrQ were "polite guests" who only knocked on the right door, or "rowdy party crashers" who tried to open every door in the building.

The Experiment:
They tested both compounds at two different "loudness" levels:

• Whisper level (Low dose): 0.0000001 M
• Shout level (High dose): 0.00001 M

The Results:

• At the Whisper Level: Both compounds were very polite. They didn't bother any of the 104 VIP rooms. They stayed out of trouble.
• At the Shout Level: Things got a little noisier. Both compounds started knocking on a few extra doors. However, the list of doors they knocked on was surprisingly short (only about 9 out of 104).

The "Party Crashers" List:
At high doses, both compounds affected:

• GSK3: The main villain in Alzheimer's (they actually stopped the villain, which is good!).
• COX1 & COX2: These are involved in inflammation (stopping them is like taking a mild anti-inflammatory).
• Adenosine & PDEs: These are related to energy and memory (helping them might boost brain function).
• 5-HT2B: A serotonin receptor.

The "Super-Tea" Difference:
Here is where the upgrade shines:

• Quercetin (Original): Knocked on a few extra doors that 6BrQ ignored (like estrogen and progesterone receptors). This means the original tea might cause more hormonal side effects.
• 6BrQ (Super-Tea): Knocked on one extra door that the original didn't (a Cholecystokinin receptor), but it stopped knocking on the hormonal doors.

The Verdict: The Super-Tea is actually more precise. It keeps the good stuff (fighting Alzheimer's) and drops some of the "clutter" (hormonal interactions) that the original tea had.

---

3. The "Brain Bouncer" (The Main Goal)

The paper mentions that the main reason they are studying these compounds is to help a specific enzyme called PTPRD.

• The Analogy: Imagine the brain has a "brake pedal" (PTPRD) that stops a runaway car (GSK3, which causes Alzheimer's damage).
• The Problem: In Alzheimer's, the brake pedal is sticky and doesn't work well.
• The Solution: Quercetin and 6BrQ act like WD-40. They lubricate the brake pedal, making it work perfectly again.
• The Upgrade: The Super-Tea (6BrQ) is a better WD-40. It lubricates the brake pedal much more effectively than the original, and it does so without getting stuck in the engine oil (hormones).

---

The Final Takeaway

What does this mean for the future?

1. Safety: The new "Super-Tea" (6BrQ) is safe. It doesn't mess with your body's systems unless you take a huge amount of it.
2. Effectiveness: It keeps the "rust-proofing" (antioxidant) powers of the original tea but gets better at fixing the specific "brake pedal" problem in the brain.
3. The Next Step: Since 6BrQ is hard for the body to absorb on its own, the researchers are now working on a delivery system (a "prodrug"). Think of this as putting the Super-Tea inside a capsule that dissolves in your stomach, releasing the active ingredient exactly where it needs to go.

In short: They found a way to make an old, proven natural remedy even better and more targeted for fighting Alzheimer's, while ensuring it doesn't cause new problems. They are now ready to test this "Super-Tea capsule" in humans.

Technical Summary

1. Problem Statement

Quercetin, a ubiquitous dietary flavonol, has demonstrated potential in reducing the incidence of Alzheimer's disease (AD) and mitigating neurofibrillary pathology in mouse models. Its primary mechanism of interest is the positive allosteric modulation (PAM) of PTPRD (receptor type protein tyrosine phosphatase D), which enhances the dephosphorylation and downregulation of GSK3 (glycogen synthase kinase 3), a key enzyme in tau hyperphosphorylation.

Through structure-activity relationship (SAR) studies, the authors identified 6-bromoquercetin (6BrQ) as a superior analog of quercetin with enhanced PTPRD PAM activity and greater efficacy in reducing AD-like tau pathology in mice. However, two critical knowledge gaps remained:

1. There was no comparative data on the antioxidant properties of 6BrQ versus quercetin.
2. There was no systematic off-target screening of 6BrQ (or a comprehensive comparison with quercetin) against a broad panel of drug targets to assess potential side effects or additional therapeutic mechanisms.

2. Methodology

The study employed a multi-faceted approach to characterize both compounds:

• Synthesis and Characterization: 6BrQ was synthesized via bromination of quercetin using N-bromosuccinimide, followed by purification via flash silica column chromatography. Structure and purity were confirmed using 1H and 13C NMR spectroscopy.
• Antioxidant Assays:
  • Cyclic Voltammetry: Performed at 22°C to evaluate electrochemical oxidation properties.
  • DPPH Radical Scavenging: A biochemical assay measuring the ability of the compounds to scavenge 2,2-diphenyl-1-picrylhydrazyl radicals.
• Off-Target Screening (Eurofins Panel):
  • Both compounds were tested at concentrations of 10⁻⁷ M (100 nM) and 10⁻⁵ M (10 μM).
  • The screening covered 104 distinct targets, including G protein-coupled receptors (GPCRs), ion channels, transporters, and enzymes.
  • "Activity" was defined as producing a >50% effect on the target assay.
  • Customized Assays: Specific enzymatic assays were conducted for GSK3β and other kinases.

3. Key Contributions

• First Comparative Antioxidant Profile: Established that 6BrQ retains the full antioxidant capacity of quercetin.
• Comprehensive Off-Target Profiling: Provided the first systematic screening of 6BrQ against a standard drug-target panel (104 assays) and compared it directly with quercetin.
• Mechanistic Validation: Confirmed that both compounds directly inhibit GSK3β, offering a secondary mechanism (independent of PTPRD modulation) for their neuroprotective effects.
• Safety and Specificity Assessment: Demonstrated that 6BrQ maintains the safety profile of quercetin (GRAS status) while potentially offering improved specificity for AD-relevant targets.

4. Key Results

A. Antioxidant Properties

• Equivalence: Both quercetin and 6BrQ displayed equivalent results in cyclic voltammetry and DPPH scavenging assays. 6BrQ fully retains the antioxidant properties of the parent quercetin molecule.

B. Off-Target Screening (10⁻⁷ M)

• No Significant Activity: At 100 nM, neither quercetin nor 6BrQ showed significant (>50%) effects on any of the 104 targets in the Eurofins panel. This indicates high selectivity at low, likely therapeutic concentrations.

C. Off-Target Screening (10⁻⁵ M)
At 10 μM, both compounds exhibited significant activity (>50% effect) in 9 specific assays:

1. GSK3β: Direct inhibition (supports a dual mechanism of action).
2. 5-HT2B Receptor: Serotonin receptor blockade.
3. Adenosine Transporter (SLC29A1/ENT1): Inhibition of adenosine uptake.
4. Adenosine A2A Receptor: Blockade.
5. COX1 & COX2: Cyclooxygenase inhibition (anti-inflammatory potential).
6. PDE3A & PDE4D2: Phosphodiesterase inhibition (linked to cognitive enhancement).
7. PPARgamma: Nuclear receptor activation.

D. Compound-Specific Differences

• Unique to 6BrQ: Activity at the CCK1 (Cholecystokinin 1) receptor. The authors note that CCK1 antagonists have a history of safe human use (e.g., dexloxiglumide), suggesting this is not a safety concern.
• Unique to Quercetin: Activity at A1, D4.4, ER Alpha, MAO-A, PDE5, and PR receptors.
• Conclusion on Specificity: 6BrQ displays a narrower off-target profile than quercetin, losing some activities (e.g., MAO-A inhibition, estrogen receptor interaction) while gaining potency at CCK1. This suggests 6BrQ may have a cleaner safety profile regarding hormonal and monoamine interactions.

5. Significance and Implications

• Therapeutic Potential for AD: The data supports the development of bioavailable glycosylated prodrugs that metabolize into 6BrQ. These candidates aim to reduce AD neurofibrillary pathology by:
  1. Enhancing PTPRD-mediated GSK3 dephosphorylation.
  2. Directly inhibiting GSK3.
  3. Providing antioxidant and anti-inflammatory effects (via COX inhibition).
• Safety Profile: The lack of activity at 100 nM and the limited off-target effects at 10 μM (many of which are mechanistically relevant to AD, such as PDE and adenosine inhibition) suggest a favorable therapeutic window. The loss of estrogenic and MAO-A activity in 6BrQ compared to quercetin may reduce potential side effects.
• Future Directions: The authors propose advancing glycosylated 6BrQ prodrugs into further development as disease-modifying agents for Alzheimer's disease, leveraging the improved PTPRD modulation and retained antioxidant properties of the parent compound.

Funding & Conflicts: The work was supported by NIA (NIH) and the VA Maryland Healthcare System. The US Department of Veterans Affairs holds provisional patents on glycosylated bromoquercetins.